Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma

Published:2017-04-13 Issue:30 Volume:8 Page:49156-49164
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Sun Xuefei¹,Liu Jing¹,Wang Yaming²,Bai Xueyan¹,Chen Yuedan¹,Qian Jun¹,Zhu Hong¹,Liu Fusheng³,Qiu Xiaoguang⁴,Sun Shengjun⁵,Ji Nan⁶,Liu Yuanbo¹

Affiliation:

1. Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

2. Department of Neurosurgery, Navy General Hospital, Beijing, China

3. Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

4. Department of Radiation Therapy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

5. Neuroimaging Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

6. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utility of contrast-enhanced MRI radiomics features combined with clinical indicators for predicting induction chemotherapy response in primary central nervous system lymphoma;Journal of Neuro-Oncology;2024-02

2. Utility of Contrast-Enhanced MRI Radiomics Features combined with clinical indicators for Predicting Induction Chemotherapy Response in Primary Central Nervous System Lymphoma;2023-11-30

3. Specific KIR-HLA genotypes predict outcomes in refractory or relapsed primary central nervous system lymphoma;Hematology;2023-08-07

4. Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma;Scientific Reports;2022-12-13

5. Specific KIR-HLA genotypes predict the outcomes of refractory or recurrent primary central nervous system lymphoma;2022-10-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3